Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo dif...
Información de la revista
Vol. 54. Núm. 7.
Páginas 390.e1-390.e16 (Agosto 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 54. Núm. 7.
Páginas 390.e1-390.e16 (Agosto 2007)
Informe de consenso
DOI: 10.1016/S1575-0922(07)71468-7
Acceso a texto completo
Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular
Visitas
...
Furio Pacinia, Martin Schlumbergerb, Henning Drallec, Rossella Eliseid, Johannes W.A. Smite, Filmar Wiersingaf, The european thyroid cancer taskforce
a Section of Endrocinology and Metabolism. University of Siena. Italia
b Service de Médicine Nucléaire. Institut Gustave Roussy. Villejuif. Francia
c Department of General, Visceral and Vascular Surgery. University of Halle. Alemania
d Department of Endocrinology. University of Pisa. Italia
e Department of Endocrinology and Metabolic Disease. Leiden University Medical Center. Países Bajos
f Department of Endocrinology and Metabolism. University of Amsterdam. Países Bajos
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Coleman PM, Babb P, Damiecky P, Groslaude P, Honjo S, Jones J, et al. Cancer Survival Trends in England and Wales 1971-1995: Deprivation and NHS Region Series SMPS no. 61. London: Stationery Office; 1999. p. 471-8.
[2.]
N.C. Hodgson, J. Button, C.C. Solorzano.
Thyroid cancer: is the incidence still increasing?.
Ann Surg Oncol, 11 (2004), pp. 1093-1097
[3.]
Guidelines for the Management of Thyroid Cancer in Adults.
Publication Unit of the Royal College of Physicians.
British Thyroid Association and Royal College of Physicians, (2002),
[4.]
F.J.C. Rodrigues, E.S. Limbert, A.P. Marques, A.P. Santos, C. Lopes, E. Rodrigues, Thyroid Study Group, et al.
Protocol for the treatment and follow-up of differentiated follicular thyroid carcinomas.
Portuguese Medical Minutes, 18 (2005), pp. 2-16
[5.]
Trattamento e Follow-up del Carcinoma Tiroideo Differenziato Della Tiroide. Linee Guida SIE-AIMN-AIFM; 2004. p. 1-75.
[6.]
C.J.H. Van De Velde, J.F. Hamming, B.M. Goslings, L.J.D.M. Schelfout, O.H. Clark, A. Smeds, et al.
Report of the consensus development conference on the management of differentiated thyroid cancer in The Netherlands.
Eur J Cancer Clin Oncol, 24 (1988), pp. 287-292
[7.]
F. Pacini, L. Burroni, C. Ciuoli, G. Di Cairano, E. Guarino.
Management of thyroid nodules: a clinicopathological, evidence-based approach.
Eur J Nuclear Med Mol Imaging, 31 (2004), pp. 1443-1449
[8.]
A. Belfiore, G.L. La Rosa, G.A. La Porta, D. Giuffrida, G. Milazzo, L. Lupo, et al.
Cancer risk in patients with cold thyroid nodules: relevance of iodine uptake, sex, age, and multinodularity.
Am J Med, 93 (1992), pp. 363-369
[9.]
E. Marqusee, C.B. Benson, M.C. Frates, P.M. Doubilet, P.R. Larsen, E.S. Cibas, et al.
Usefulness of ultrasonography in the management of nodular thyroid disease.
Ann Intern Med, 133 (2000), pp. 696-700
[10.]
M.C. Frates, C.B. Benson, J.W. Charboneau, E.S. Cibas, O.H. Clark, B.G. Coleman, Society of Radiologists in Ultrasound, et al.
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement.
Radiology, 237 (2005), pp. 794-800
[11.]
L. Hegedus.
Thyroid ultrasound.
Endocrinol Metab Clin North Am, 30 (2001), pp. 339-360
[12.]
J. Cap, A. Riska, P. Rehorkova, E. Hovorkova, Z. Kerekes, D. Pohnetalova.
Sensitivity and specificity of the fine needle aspiration biopsy of the thyroid: clinical point of view.
Clin Endocrinol, 51 (1999), pp. 509-515
[13.]
M. Braga, T.C. Cavalcanti, L.M. Collaco, H. Graf.
Efficacy of ultrasound-guided fine-needle aspiration biopsy in the diagnosis of complex thyroid nodules.
J Clin Endocrinol Metab, 86 (2001), pp. 4089-4091
[14.]
M.M. Mulcahy, J.I. Cohen, P.E. Anderson, J. Ditamasso, W. Schmidt.
Relative accuracy of fine-needle aspiration and frozen section in the diagnosis of well-differentiated thyroid cancer.
Laryngoscope, 104 (1998), pp. 494-496
[15.]
D. Giuffrida, H. Gharib.
Anaplastic thyroid cancer: current diagnosis and treatment.
Ann Oncol, 11 (2000), pp. 1083-1089
[16.]
E.L. Mazzaferri, S.M. Jhiang.
Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
Am J Med, 49 (1994), pp. 418-428
[17.]
R.E. Goldstein, J.L. Netterville, B. Burkey, J.E. Johnson.
Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules.
Ann Surg, 235 (2002), pp. 656-662
[18.]
E. Guarino, B. Tarantini, T. Pilli, S. Checchi, L. Brilli, C. Ciuoli, et al.
Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancer.
Thyroid, 15 (2005), pp. 1041-1045
[19.]
R. Elisei, V. Bottici, F. Luchetti, G. Di Coscio, C. Romei, L. Grasso, et al.
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders.
J Clin Endocrinol Metab, 89 (2004), pp. 163-168
[20.]
P. Niccoli, N. Wion-Barbot, P. Caron, J.F. Henry, C. De Micco, J.P. Saint Andre, et al.
Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group.
J Clin Endocrinol Metab, 82 (1997), pp. 338-341
[21.]
M. Rieu, M.C. Lame, A. Richard, B. Lissak, B. Sambort, P. Vuong-Ngoc, et al.
CT prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules.
Clin Endocrinol (Oxford), 42 (1995), pp. 453-460
[22.]
H. Vierhapper, W. Raber, C. Bieglmayer, K. Kaserer, A. Weinhausl, B. Niederle.
Routine measurement of plasma calcitonin in nodular thyroid diseases.
J Clin Endocrinol Metab, 82 (1997), pp. 1589-1593
[23.]
K. Shimamoto, H. Satake, A. Sawaki, T. Ishigaki, H. Funahashi, T. Imai.
Preoperative staging of thyroid papillary carcinoma with ultrasonography.
Eur J Radiol, 29 (1998), pp. 4-10
[24.]
N.F. Esnaola, S.B. Cantor, S.I. Sherman, J.E. Le, D.B. Evans.
Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis.
Surgery, 130 (2001), pp. 921-930
[25.]
I.D. Hay, E.J. Bergstralh, J.R. Goellner, J.R. Ebersold, C.S. Grant.
Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.
Surgery, 114 (1993), pp. 1050-1058
[26.]
I.D. Hay, C.S. Grant, E.J. Bergstralh, G.B. Thompson, J.A. Van Heerden, J.R. Goellner.
Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?.
Surgery, 124 (1998), pp. 958-966
[27.]
S.A. Hundahl, B. Cady, M.P. Cunningham, E. Mazzaferri, R.F. Mc-Kee, J. Rosai, et al.
Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996.
Cancer, 89 (2000), pp. 202-217
[28.]
A. Machens, H.J. Holzhausen, H. Dralle.
The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma.
Cancer, 103 (2005), pp. 2269-2273
[29.]
R.E. Gardner, R.M. Tuttle, K.D. Burman, S. Haddady, C. Truman, Y.H. Sparling, et al.
Prognostic importance of vascular invasion in papillary thyroid carcinoma.
Arch Otolaryngol Head Neck Surg, 126 (2000), pp. 309-312
[30.]
F. Pacini, R. Elisei, M. Capezzone, P. Miccoli, E. Molinaro, F. Basolo, et al.
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients.
Thyroid, 11 (2001), pp. 877-881
[31.]
A. Machens, R. Hinze, C. Lautenschläger, O. Thomusch, H. Dralle.
Prophylactic completion thyroidectomy for differentiated thyroid carcinoma: prediction of extrathyroidal soft tissue infiltrates.
Thyroid, 11 (2001), pp. 381-384
[32.]
G.W. Randolph, G.H. Daniels.
Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid.
Thyroid, 12 (2002), pp. 989-996
[33.]
Y. Ito, C. Tomoda, T. Uruno, Y. Takamura, A. Miya, K. Kobayashi, et al.
Preoperative ultrasonographic examination for lymph node metastases: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid.
World J Surg, 28 (2004), pp. 498-501
[34.]
A. Machens, R. Hinze, O. Thomusch, H. Dralle.
Pattern of nodal metastasis for primary and reoperative thyroid cancer.
World J Surg, 26 (2002), pp. 22-28
[35.]
G.F. Scheumann, O. Gimm, G. Wegener, H. Hundeshagen, H. Dralle.
Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer.
World J Surg, 18 (1994), pp. 559-568
[36.]
L.E. Tisell, B. Nilsson, J. Molne, G. Hansson, M. Fyalling, S. Janson, et al.
Improved survival of patients with papillary thyroid cancer after surgical microdissection.
World J Surg, 20 (1996), pp. 854-859
[37.]
H. Dralle, M. Brauckhoff, A. Machens, O. Gimm.
Surgical management of advanced thyroid cancer invading the aerodigestive tract.
Textbook of Endocrine Surgery, 2.ª ed., pp. 318-333
[38.]
O. Thomusch, C. Sekulla, G. Walls, M. Fasshauer, H. Dralle.
Analysis of surgery-related complications in thyroid carcinoma –a German prospective multi-centre study with 275 patients.
Acta Chirurgica Austriaca, 33 (2001), pp. 194-198
[39.]
D.M. Hartl, J.P. Travagli, S. Leboulleux, E. Baudin, D.F. Brasnu, M. Schlumberger.
Current concepts in the management of unilateral recurrent laryngeal nerve paralysis after thyroid surgery.
J Clin Endocrinol Metab, 90 (2005), pp. 3084-3088
[40.]
N.A. Samaan, P.N. Schultz, R.C. Hickey, H. Goepfert, T.P. Haynie, D.A. Johnston, et al.
The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.
J Clin Endocrinol Metab, 75 (1992), pp. 714-720
[41.]
E.L. Mazzaferri, S.M. Jhiang.
Differentiated thyroid cancer: long-term impact of initial therapy.
Transactions of the American Clinical and Climatological Association, 106 (1994), pp. 151-168
[42.]
T. Taylor, B. Specker, J. Robbins, M. Sperlin, M. Ho, K. Ain, et al.
Outcome after treatment of high-risk papillary and non-Hurthlecell follicular thyroid carcinoma.
Ann Intern Med, 129 (1998), pp. 622-627
[43.]
A.M. Sawka, K. Thephamongkhol, M. Brouwers, L. Thabane, G. Browman, H.C. Gerstein.
Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.
J Clin Endocrinol Metab, 89 (2004), pp. 3668-3676
[44.]
F. Pacini, M. Schlumberger, C. Harmer, G. Berg, O. Cohen, L. Duntas, et al.
Post surgical use of radioiodine (I-131) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation. A consensus report.
Eur J Endocrinol, 153 (2005), pp. 651-659
[45.]
P.R. Schroder, B.R. Haughen, F. Pacini, C. Rainers, M. Schlumberger, S.I. Sherman, et al.
A comparison of short term changes in health related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with rhTSH compared to thyroid hormone withdrawal.
J Clin Endocrinol Metab, 91 (2006), pp. 878-884
[46.]
M. Schlumberger, P. Charbord, P. Fragu, J. Lumbroso, C. Parmentier, M. Tubiana.
Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyrotropin levels.
J Clin Endocrinol Metab, 51 (1980), pp. 513-519
[47.]
R.J. Robbins, S.M. Larson, N. Sinha, A. Shaha, C. Divgi, K.S. Pentlow, et al.
A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.
J Nuclear Med, 43 (2002), pp. 1482-1488
[48.]
F. Pacini, P.W. Ladenson, M. Schlumberger, A. Driedger, M. Luster, R.T. Kloos, et al.
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.
J Clin Endocrinol Metab, 91 (2006), pp. 926-932
[49.]
H.M. Park, Y.H. Park, X.H. Zhou.
Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma.
Thyroid, 7 (1997), pp. 277-280
[50.]
T.E. Hilditch, M.F. Dempsey, A.A. Bolster, R.M. McMenemin, N.S. Reed.
Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic I-131 and I-123.
Eur J Nuclear Med Mol Imaging, 29 (2002), pp. 783-788
[51.]
M. Lassmann, M. Luster, H. Hanscheid, C. Reiners.
Impact of 131I diagnostic activities on the biokinetics of thyroid remnants.
J Nuclear Med, 45 (2004), pp. 619-625
[52.]
M.J. Pluijmen, C. Eustatia-Rutten, B.M. Goslings, M.P. Stokkel, A.M. Arias, M. Diamant, et al.
Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma.
Clin Endocrinol (Oxford), 58 (2003), pp. 428-435
[53.]
V. Fatourechi, I.D. Hay, B.P. Mullan, G.A. Wiseman, G.Z. Eghbali-Faotoreki, L.M. Thorson, et al.
Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?.
Thyroid, 10 (2000), pp. 573-577
[54.]
S.I. Sherman, E.T. Tielens, S. Sostre, M.D. Wharam Jr., P.W. Ladenson.
Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma.
J Clin Endocrinol Metab, 78 (1994), pp. 629-634
[55.]
I.D. Hay, E.J. Bergstralh, J.R. Goellner, J.R. Ebersold, C.S. Grant.
Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.
Surgery, 114 (1993), pp. 1050-1057
[56.]
I.D. Hay, G.B. Thompson, C.S. Grant, E.J. Bergstralh, C.E. Dvorak, C.A. Gorman, et al.
Papillary thyroid carcinoma managed at the May Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.
World J Surg, 8 (2002), pp. 879-885
[57.]
D.P. Byar, S.B. Green, P. Dor, E.D. Williams, J. Colon, H.A. Van Gilse, et al.
A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group.
Eur J Cancer, 15 (1979), pp. 1033-1041
[58.]
J. Tenvall, A. Biorklund, T. Moller, J. Ranstam, M. Akerman.
Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow-up.
Cancer, 57 (1986), pp. 1405-1414
[59.]
A.R. Shaha, T.R. Loree, J.P. Shah.
Prognostic factors and risk group analysis in follicular carcinoma of the thyroid.
Surgery, 118 (1995), pp. 1131-1136
[60.]
S.I. Sherman, J.D. Brierley, M. Sperling, K.B. Ain, S.T. Bigos, D.S. Cooper, et al.
Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group.
Cancer, 83 (1998), pp. 1012-1021
[61.]
T.P. Links, K.M. Van Tol, P.L. Jager, J.Th.M. Plukker, D.A. Piers, H.M. Boezen, et al.
Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis.
Endocrine-related Cancer, 12 (2005), pp. 272-280
[62.]
C. Wittekind, C.C. Compton, F.L. Greene, L.H. Sobin.
TNM residual tumor classification revisited.
Cancer, 94 (2002), pp. 2511-2516
[63.]
D.S. Cooper, B. Specker, M. Ho, M. Sperling, P.W. Ladenson, D.S. Ross, et al.
Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
Thyroid, 8 (1998), pp. 737-744
[64.]
N.J. McGriff, G. Csako, L. Gourgiotis, C.G. Lori, F. Pucino, N.J. Sarlis.
Effects of thyroid hormone suppression therapy on adverse. clinical outcomes in thyroid cancer.
Ann Med, 34 (2002), pp. 554-564
[65.]
E. Baudin, C. Do Cao, A.F. Cailleux, S. Leboulleux, J.P. Travagli, M. Schlumberger.
Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
J Clin Endocrinol Metab, 88 (2003), pp. 1107-1111
[66.]
M. Schlumberger, G. Berg, O. Cohen, L. Duntas, F. Jamar, B. Jarzab, et al.
Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.
Eur J Endocrinol, 150 (2004), pp. 105-112
[67.]
B. Biondi, S. Filetti, M. Schlumberger.
Thyroid-hormone therapy and thyroid cancer: a reassessment.
Nat Clin Pract Endocrinol Metab, 1 (2005), pp. 32-40
[68.]
M.K. Horne 3rd, K.K. Singh, K.G. Rosenfeld, R. Wesley, M.C. Skarulis, P.K. Merryman, et al.
Is thyroid hormone suppression therapy prothrombotic?.
J Clin Endocrinol Metab, 89 (2004), pp. 4469-4473
[69.]
U. Feldt-Rasmussen, C. Profilis, E. Colinet, E. Black, H. Bornet, P. Bourdoux, et al.
Human thyroglobulin reference material (CRM 457). 1st part: assessment of homogeneity, stability and immunoreactivity.
Annales de Biologie Clinique (Paris), 54 (1996), pp. 337-342
[70.]
U. Feldt-Rasmussen, C. Profilis, E. Colinet, E. Black, H. Bornet, P. Bourdoux, et al.
Human thyroglobulin reference material (CRM 457). 2nd part: physicochemical characterization and certification.
Annales de Biologie Clinique (Paris), 54 (1996), pp. 343-348
[71.]
L. Chiovato, F. Latrofa, L.E. Braverman, F. Pacini, M. Capezzone, L. Masserini, et al.
Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens.
Ann Intern Med, 139 (2003), pp. 346-351
[72.]
A.F. Cailleux, E. Baudin, J.P. Travagli, M. Ricard, M. Schlumberger.
Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid carcinoma?.
J Clin Endocrinol Metab, 85 (2000), pp. 175-178
[73.]
F. Pacini, M. Capezzone, R. Elisei, C. Ceccarelli, D. Taddei, A. Pinchera.
Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
J Clin Endocrinol Metab, 87 (2002), pp. 1499-1501
[74.]
F. Pacini, E. Molinaro, M.G. Castagna, L. Agate, R. Elisei, C. Ceccarelli, et al.
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
J Clin Endocrinol Metab, 88 (2003), pp. 3668-3673
[75.]
M. Torlontano, M. Attard, U. Crocetti, S. Tumino, R. Bruno, G. Costante, et al.
Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases.
J Clin Endocrinol Metab, 89 (2004), pp. 3402-3407
[76.]
F. Pacini, E. Molinaro, F. Lippi, M.G. Castagna, L. Agate, C. Ceccarelli, et al.
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
J Clin Endocrinol Metab, 86 (2001), pp. 5686-5690
[77.]
M. Schlumberger, O. Arcangioli, J.D. Piekarski, M. Tubiana, C. Parmentier.
Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays.
J Nuclear Med, 29 (1988), pp. 1790-1794
[78.]
J.D. Pineda, T. Lee, K. Ain, J.C. Reynolds, J. Robbins.
Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan.
J Clin Endocrinol Metab, 80 (1995), pp. 1488-1492
[79.]
F. Pacini, L. Agate, R. Elisei, M. Capezzone, C. Ceccarelli, F. Lippi, et al.
Outcome of differentiated thyroid cancer with detectable serum thyroglobulin and negative diagnostic 131I whole body scan: comparison of patients treated with high 131I activities versus untreated patients.
J Clin Endocrinol Metab, 86 (2001), pp. 4092-4097
[80.]
M. Luster, F. Lippi, B. Jarzab, P. Perros, M. Lassmann, C. Reiners, et al.
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Endocrine-related Cancer, 12 (2005), pp. 49-64
[81.]
B.R. Haugen, F. Pacini, C. Reiners, M. Schlumberger, P.W. Ladenson, S.I. Sherman, et al.
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
J Clin Endocrinol Metab, 84 (1999), pp. 3877-3885
[82.]
A.A. Driedger, N. Kotowycz.
Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin.
J Clin Endocrinol Metab, 89 (2004), pp. 585-590
[83.]
W. Wang, H. Macapinlac, S.M. Larson, S.D. Yeh, T. Akhurst, R.D. Finn, et al.
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels.
J Clin Endocrinol Metab, 84 (1999), pp. 2291-2302
[84.]
B.O. Helal, P. Merlet, M.E. Toubert, B. Franc, C. Schvartz, H. Gauthier-Koelesnikov, et al.
Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy.
J Nuclear Med, 42 (2001), pp. 1464-1469
[85.]
B.B. Chin, P. Patel, C. Cohade, M. Ewertz, R. Wahl, P. Ladenson.
Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma.
J Clin Endocrinol Metab, 89 (2004), pp. 91-95
[86.]
Z. Nahas, D. Goldenberg, C. Fakhry, M. Ewertz, M. Zeiger, P.W. Ladenson, et al.
The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma.
Laryngoscope, 115 (2005), pp. 237-243
[87.]
R.J. Robbins, Q. Wan, R.K. Grewal, R. Reibke, M. Gonen, H.W. Strauss, et al.
Real-time prognosis for metastatic thyroid carcinoma based on FDG-PET scanning.
J Clin Endocrinol Metab, 91 (2006), pp. 498-505
[88.]
M. Schlumberger, F. Pacini, W.M. Wiersinga, A. Toft, J.W. Smit, F. Sanchez Franco, et al.
Follow-up and management of differentiated thyroid carcinoma: European perspective in clinical practice.
Eur J Endocrinol, 151 (2004), pp. 539-548
[89.]
M. Schlumberger, M. Ricard, F. Pacini.
Clinical use of recombinant human TSH in thyroid cancer patients.
Eur J Endocrinol, 143 (2000), pp. 557-563
[90.]
E.L. Mazzaferri, R.J. Robbins, C.A. Spencer, L.E. Braverman, F. Pacini, L. Wartofsky, et al.
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
J Clin Endocrinol Metab, 88 (2003), pp. 1433-1441
[91.]
R.D. Leeper.
The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma.
J Clin Endocrinol Metab, 36 (1973), pp. 1143-1152
[92.]
W.H. Beierwaltes, R.H. Nishiyama, N.W. Thompson, J.E. Copp, A. Kubo.
Survival time and ‘cure’ in papillary and follicular thyroid carcinoma with distant metastases: statistics following University ofMichigan therapy.
J Nuclear Med, 23 (1982), pp. 561-568
[93.]
M.O. Bernier, L. Leenhardt, C. Hoang, A. Aurengo, J.Y. Mary, F. Menegaux, et al.
Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas.
J Clin Endocrinol Metab, 86 (2001), pp. 1568-1573
[94.]
F. Pacini, F. Cetani, P. Miccoli, F. Mancusi, C. Ceccarelli, F. Lippi, et al.
Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine.
World J Surg, 18 (1994), pp. 600-604
[95.]
F. Pons, I. Carrio, M. Estorch, M. Ginjaume, J. Pons, R. Milian.
Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma.
Clin Nuclear Med, 12 (1987), pp. 644-647
[96.]
S.S. Koong, J.C. Reynolds, E.G. Movius, A.M. Keenan, K.B. Ain, M.C. Lakshmanan, et al.
Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma.
J Clin Endocrinol Metab, 84 (1999), pp. 912-916
[97.]
G. Zettinig, B.J. Fueger, C. Passler, K. Kaserer, C. Pirich, R. Dudczak, et al.
Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma – surgery or conventional therapy?.
Clin Endocrinol (Oxford), 56 (2002), pp. 377-382
[98.]
A.G. Pittas, M. Adler, M. Fazzari, S. Tickoo, J. Rosai, S.M. Larson, et al.
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred fortysix patients.
Thyroid, 10 (2000), pp. 261-268
[99.]
M. Schlumberger, C. Challeton, F. De Vathaire, J.-P. Travagli, P. Gardet, J.-D. Lumbroso, et al.
Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.
J Nuclear Med, 37 (1996), pp. 598-605
[100.]
C. Marcocci, F. Pacini, R. Elisei, E. Schipani, C. Ceccarelli, P. Miccoli, et al.
Clinical and biological behaviour of bone metastases from differentiated thyroid carcinoma.
Surgery, 106 (1989), pp. 960
[101.]
R.R. McWilliams, C. Giannini, I.D. Hay, J.L. Atkinson, S.L. Stafford, J.C. Buckner.
Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years.
Cancer, 98 (2003), pp. 356-362
[102.]
S.J. Mandel, L. Mandel.
Radioactive iodine and the salivary glands.
Thyroid, 13 (2003), pp. 265-271
[103.]
K. Nakada, T. Ishibashi, T. Takei, K. Hirata, K. Shinohara, S. Katoh, et al.
Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?.
J Nuclear Med, 46 (2005), pp. 261-266
[104.]
C. Ceccarelli, P. Battisti, M. Gasperi, E. Fantuzzi, F. Pacini, G. Gualdrini, et al.
Radiation dose to the testes after 131-I therapy for ablation of post-surgical thyroid remnants in patients with differentiated thyroid cancer.
J Nuclear Med, 40 (1999), pp. 1716-1721
[105.]
F. Pacini, M. Gasperi, L. Fugazzola, C. Ceccarelli, F. Lippi, R. Centoni, et al.
Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine.
J Nuclear Med, 35 (1994), pp. 1418-1422
[106.]
M. Schlumberger, F. De Vathaire, C. Ceccarelli, M.J. Delisle, C. Francese, J.E. Couette, et al.
Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients.
J Nuclear Med, 37 (1996), pp. 606-612
[107.]
C. Ceccarelli, W. Benicivelli, D. Morciano, A. Pinchera, F. Pacini.
131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study.
J Clin Endocrinol Metab, 86 (2001), pp. 3512-3515
[108.]
C. Rubino, F. De Vathaire, M.E. Dottorini, P. Hall, C. Schvartz, J.E. Couette, et al.
Second primary malignancies in thyroid cancer patients.
Br J Cancer, 89 (2003), pp. 1638-1644
[109.]
F. De Vathaire, M. Schlumberger, M.J. Delisle, C. Francese, C. Challeton, E. De la Genardiere, et al.
Leukaemias and cancers following iodine-131 administration for thyroid cancer.
Br J Cancer, 75 (1997), pp. 734-739
[110.]
D. Ford, S. Giridharan, C. McConkey, A. Hartley, C. Brammer, J.C. Watkinson, et al.
External beam radiotherapy in the management of differentiated thyroid cancer.
Clin Oncol, 15 (2003), pp. 337-341
[111.]
R. Mazzarotto, M.G. Cesaro, O. Lora, D. Rubello, D. Casara, G. Sotti.
The role of external beam radiotherapy in the management of differentiated thyroid cancer.
Biomed Pharmacother, 54 (2000), pp. 345-349
[112.]
J.P. Droz, M. Schlumberger, P. Rougier, M. Ghosn, P. Gardet, C. Parmentier.
Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy.
Tumori, 76 (1990), pp. 480-483
[113.]
F. Pacini, P. Vitti, E. Martino, C. Giani, G. Bambini, A. Pinchera, et al.
Treatment of refractory thyroid cancer with adriamycin.
Drugs Exper Clin Res, 10 (1984), pp. 911-916
[114.]
B.R. Haugen.
Management of the patient with progressive radioiodine non-responsive disease.
Semin Surg Oncol, 16 (1999), pp. 34-41
[115.]
F. Santini, V. Bottici, R. Elisei, L. Montanelli, S. Mazzeo, F. Basolo, et al.
Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer.
J Clin Endocrinol Metab, 87 (2002), pp. 4160-4165
[116.]
M. Braga-Brasaria, M.D. Ringel.
Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer.
J Clin Endocrinol Metab, 88 (2003), pp. 1947-1960
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.